Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | TSHR | P16473 | 8/20 | 0.44 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850151 | 0.86 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 | |
| SCHEMBL11679914 | 0.77 | MGAM (0.42) | HSP90AA1HSP90AB1TP53ADORA3ADORA2A | |
| SCHEMBL3942360 | 0.77 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1ADORA3ADORA2AADORA2B | |
| SCHEMBL15486382 | 0.76 | CDK9 (0.49) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 | |
| SCHEMBL8514899 | 0.76 | CYP1A2 (0.48) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 | |
| SCHEMBL30777916 | 0.76 | CYP1A2 (0.48) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 | |
| SCHEMBL27534760 | 0.75 | CCNT1 (0.49) | CYP1A2CYP2C19CLK4CYP2D6CYP3A4 | |
| SCHEMBL2988060 | 0.74 | CLK4 (0.43) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 | |
| SCHEMBL15533294 | 0.74 | CYP1A2 (0.50) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 | |
| SCHEMBL4431846 | 0.74 | CYP1A2 (0.44) | HSP90AA1HSP90AB1CYP1A2CYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2137166-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-2137164-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008132138-A1 | DERIVATIVES OF 4,6-DISUBSTITUTED AMINOPYRIMIDINES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK2, CDK6, CDK5 | HSP90AA1 991/4885HSP90AB1 970/4885CYP1A2 3578/4885 |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK6, CDK2, CDK1 | HSP90AA1 1005/4885HSP90AB1 965/4885CYP1A2 2965/4885 |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | CDK5, CDK5R1, CDK4 | HSP90AA1 970/4885HSP90AB1 1160/4885CYP1A2 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.